Jaguar Health

Jaguar Health, Inc. is a commercial stage pharmaceuticals company, which engages in the development of gastrointestinal products. The firm focuses on developing novel, plant-based, non-opioid, and sustainably derived prescription medicines for people and animals with GI distress, specifically chronic, debilitating diarrhea. It operates through the Human Health and Animal Health segments. The Human Health segment manufactures human products and the ongoing advertising of Mytesi, which is used for the symptomatic relief of non-infectious diarrhea in adults with HIV/AIDS on antiretroviral therapy. The Animal Health segment commercializes prescription and non-prescription products for companion and production animals. The company was founded by Lisa A. Conte on June 6, 2013 and is headquartered in San Francisco, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Jaguar Health reports revenue growth and eyes cancer therapy market

Jaguar Health's Q1 2024 performance showed revenue growth and improved financial metrics. The company's strategic focus on cancer supportive care and rare diseases positions it for future growth. Challenges include trial result uncertainties and regulatory timelines, but opportunities exist in market expansion and new programs.

Jaguar Health reports revenue growth and promising clinical trial results

Jaguar Health's Q2 2024 earnings call showcases revenue growth, positive clinical trial outcomes, and strategic plans for product launches and FDA discussions. The company's focus on improving patient outcomes and expanding its product reach positions it for future success in the healthcare market.

Jaguar Health reports revenue growth and advances in cancer care

Jaguar Health's Q3 performance reflects revenue growth, successful trial outcomes, and a focus on cancer patient care through innovative products.
While facing challenges in regulatory processes and financial metrics, the company is well-positioned to capitalize on opportunities in rare diseases and oncology.
Overall, Jaguar Health's strategic initiatives and commitment to addressing critical medical needs position it for potential growth and impact in the healthcare sector.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Jaguar Health, Inc. is a commercial stage pharmaceuticals company, which engages in the development of gastrointestinal products. It operates through the Human Health and Animal Health segments. The Human Health segment is involved in manufacturing human products and the ongoing advertising of Mytesi, which is used for the symptomatic relief of non-infectious diarrhea in adults with HIV/AIDS on antiretroviral therapy. The Animal Health segment includes commercializing prescription and non-prescription products for companion and production animals. The company was founded by Lisa A. Conte on June 6, 2013 and is headquartered in San Francisco, CA.

Dr. Radaelli appointed Interim Executive Director of Napo Therapeutics S.p.A., the corporation established by Jaguar Health in Italy in 2021 that focuses on expanding crofelemer access in Europe SAN FRANCISCO, CA / ACCESSWIRE / June 7, 2023 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar") today announced that on April 24, 2023, Massimo Radaelli, PhD, a European pharmaceutical industry leader and entrepreneur with more than 30 years of experience in the biopharmaceutical sector and innovation in therapies dedicated to rare diseases, was named Commander of the Italian Republic for Special Merits, the highest ranking honor of the Italian Republic bestowed upon a civilian by the President of the Republic of Italy and the Prime Minister of Italy, in recognition for "merit acquired in the fields of Science and the BioPharma Industry with a particular focus in Rare and Neglected diseases.

European Pharmaceutical Industry Leader and Entrepreneur Massimo Radaelli, PhD Named Commander of the Italian Republic for Special Merits

256-patient enrollment target met plus 11% over-enrollment; Primary endpoint based on patient reported outcomes from study expected in October 2023 SAN FRANCISCO, CA / ACCESSWIRE / May 25, 2023 / Jaguar Health, Inc. (Nasdaq:JAGX) ("Jaguar" or the "Company") today announced that the Company has successfully over-enrolled its global, pivotal, Phase 3 OnTarget clinical trial of crofelemer for prophylaxis of diarrhea in adult cancer patients receiving targeted therapy with or without chemotherapy. "As anticipated, we over-enrolled our ongoing placebo-controlled OnTarget trial by 11% after completion of the targeted enrollment of 256 patients," said Pravin Chaturvedi, PhD, Jaguar's Chair of the Scientific Advisory Board and Chief Scientific Officer, "and we look forward to the expected availability of top line results from this study in October 2023.

Jaguar Announces Over-Enrollment in its Pivotal Phase 3 OnTarget Trial of Crofelemer for Prophylaxis of Cancer Therapy-Related Diarrhea

SAN FRANCISCO, CA / ACCESSWIRE / May 24, 2023 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") today announced that Stacey Tinianov, MPH, a Board Certified Patient Advocate, has joined the Company's Scientific Advisory Board (SAB). "We are very pleased that Stacey has joined our SAB," said Pravin Chaturvedi, PhD, Jaguar's Chair of the Scientific Advisory Board and Chief Scientific Officer.

Board Certified Patient Advocate Stacey Tinianov, MPH, Joins Jaguar Health's Scientific Advisory Board

Announces Focus on Four Cancers Common to Children & Canines for Upcoming Capitol Hill Briefing, Commitment to Advancing Comparative Oncology According to the National Cancer Institute, Roughly 6 Million New Cancer Diagnoses are Made in Dogs Each Year in the U.S. SAN FRANCISCO, CA / ACCESSWIRE / May 23, 2023 / Jaguar Health, Inc. (NASDAQ:JAGX) announced the one-year anniversary of the Take C.H.A.R.G.E. (Canine Health And ReGistry Exchange) and an approximately 40 percent increase in canine cancer records on the second annual National Canine Cancer Awareness Day (May 23rd).

Take C.H.A.R.G.E. Registry Marks One-Year Anniversary on National Canine Cancer Awareness Day, With Database Grown 40%

SAN FRANCISCO, CA / ACCESSWIRE / May 19, 2023 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") announced today that the Company's New Employee Inducement Award Plan (the "Inducement Award Plan"), which was adopted by Jaguar's Board of Directors effective June 16, 2020, has been replenished with 499,171 shares of the Company's common stock, par value $0.0001 per share (the "Common Stock"). These 499,171 shares are in addition to (a) the 2,222 shares of Common Stock registered on the Company's Form S-8 filed on May 28, 2021 (File No.

Jaguar Health Announces Replenishment of New Employee Inducement Plan Under Nasdaq Listing Rule 5635(c)(4)

Jaguar Animal Health's Canalevia®-CA1 is the first and only treatment for chemotherapy-induced diarrhea (CID) in dogs to receive FDA conditional approval and is widely available through prominent pet retailers in the U.S. SAN FRANCISCO, CA / ACCESSWIRE / May 16, 2023 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") today announced that on Thursday, May 18, 2023 Lisa Conte, Jaguar's president, founder, and CEO, will present at the virtual Lytham Partners Spring 2023 Investor Conference and take part in an Animal Health Panel Discussion during the event. Company Webcast The Company's webcast presentation will be available for online viewing at 9:00 a.m.

Jaguar Health to Present at Lytham Partners Spring 2023 Investor Conference & Participate in Animal Health Panel

Jaguar Health, Inc. (NASDAQ:JAGX ) Q1 2023 Earnings Conference Call May 15, 2023 8:30 AM ET Company Participants Lisa Conte - President & Chief Executive Officer Sandra Swain - Professor of Medicine, Georgetown Kelly Shanahan - Patient Advocate Carol Lizak - Chief Financial Officer Ian Wendt - Chief Commercial Officer Conference Call Participants Operator Greetings and welcome to the Jaguar Health Investor Webcast. [Operator Instructions] Before I turn the call over to management, I'd like to remind you that management may make forward-looking statements relating to such matters as continued growth prospects for the company, uncertainties regarding market acceptance of products, the impact of competitive products and pricing, industry trends and product initiatives, including products in the development stage which may not achieve scientific objectives or meet stringent regulatory requirements.

Jaguar Health, Inc. (JAGX) Q1 2023 Earnings Call Transcript

Net revenue decreased in Q1 2023 versus Q1 2022 Net loss improved over the same period Jaguar has agreed, as described below, not to issue additional equity securities before October 22, 2023 - by which point the Company expects to have released top line data for the Phase 3 OnTarget trial Completed and core near-term milestones: Enrollment completed for Phase 3 OnTarget trial Submission of Investigational New Drug (IND) application planned for Q2 2023 to FDA for crofelemer for microvillus inclusion disease REMINDER: Jaguar to host investor webcast Monday, May 15th at 8:30 a.m. Eastern regarding first-quarter 2023 financials and company updates; Click here to register for webcast SAN FRANCISCO, CA / ACCESSWIRE / May 15, 2023 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") today reported consolidated first-quarter 2023 financial results and provided Company updates.

Jaguar Health Reports First Quarter 2023 Financial Results

Click here to register for webcast Company plans to file its Earnings Report on May 15, 2023 on Form 10-Q for the quarter ended March 31, 2023 SAN FRANCISCO, CA / ACCESSWIRE / May 12, 2023 / Jaguar Health, Inc. (NASDAQ:JAGX) today issued a reminder that the company will conduct an investor webcast on Monday, May 15, 2023 at 8:30 a.m. Eastern Daylight Time to review first-quarter 2023 financials and provide corporate updates.

REMINDER: Jaguar Health to Hold Investor Webcast Monday, May 15th at 8:30 AM EDT Regarding Q1 2023 Financials & Corporate Updates

Canalevia®-CA1 is the first and only treatment for CID in dogs to receive any type of approval from the FDA SAN FRANCISCO, CA / ACCESSWIRE / May 11, 2023 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") under its Jaguar Animal Health tradename for the veterinary market, today announced that Canalevia-CA1 (crofelemer delayed-release tablets), the company's U.S. Food and Drug Administration (FDA) conditionally approved prescription drug product for the treatment of chemotherapy-induced diarrhea (CID) in dogs, is now available on Chewy , a trusted destination for pet parents and partners everywhere. "We are thrilled to have added Chewy to the list of prominent pet retailers in the U.S. that offer Canalevia-CA1.

Canalevia-CA1, Jaguar Animal Health's FDA Conditionally Approved Drug for Chemotherapy-Induced Diarrhea (CID) in Dogs, Now Available from Chewy

AI technology is expected to help make it faster and easier for Mytesi® patients to start and stay on the drug SAN FRANCISCO, CA / ACCESSWIRE / May 10, 2023 / Jaguar Health, Inc. (Nasdaq:JAGX) ("Jaguar" or the "Company") today announced that the Company has launched an artificial intelligence-powered web portal for U.S. healthcare professionals to support patient access to Mytesi (crofelemer), the Company's FDA-approved antidiarrheal prescription drug indicated for the symptomatic relief of noninfectious diarrhea in adult patients with HIV/AIDS on antiretroviral therapy. Access to the portal is available to U.S. healthcare professionals on the Mytesi Healthcare Professionals Site.

Jaguar Health Launches AI-powered Web Portal to Support Patient Access to Mytesi, the Company's FDA-approved Prescription Drug

Primary endpoint based on patient reported outcomes from study expected in October 2023 With the completion of the PIPE financing of unregistered shares and 6-month lock up term, Jaguar has agreed, as described below, not to issue additional equity securities before October 22, 2023 - by which point the Company expects to have released top line data for the OnTarget trial SAN FRANCISCO, CA / ACCESSWIRE / May 9, 2023 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") today announced that it has completed enrolling the target number of 256 patients in the Company's global, pivotal, Phase 3 OnTarget clinical trial of crofelemer for prophylaxis of diarrhea in adult cancer patients receiving targeted therapy with or without chemotherapy. "The Company's current cash position includes anticipated gross proceeds from a PIPE (private investment in public equity) transaction of approximately $1.86 million involving the issuance and sale of approximately 3,425,000 shares of unregistered Jaguar Common Stock and 6,850,000 warrants not exercisable until the later of January 1, 2024 and stockholder approval, that is expected to close on May 9, 2023, subject to customary closing conditions," said Lisa Conte, Jaguar's president and CEO.

Jaguar Completes Enrollment in Its Pivotal Phase 3 OnTarget Trial of Crofelemer for Prophylaxis of Cancer Therapy-Related Diarrhea

Click here to register for webcast Company plans to file its Earnings Report on May 15, 2023 on Form 10-Q for the quarter ended March 31, 2023 SAN FRANCISCO, CA / ACCESSWIRE / May 8, 2023 / Jaguar Health, Inc. (NASDAQ:JAGX) today announced that the company will conduct an investor webcast on Monday, May 15, 2023 at 8:30 a.m. Eastern Daylight Time to review first-quarter 2023 financials and provide corporate updates.

Jaguar Health to Hold Investor Webcast Monday, May 15th at 8:30 AM EDT Regarding Q1 2023 Financials & Corporate Updates

Proof-of-concept studies of crofelemer in patients with short bowel syndrome (SBS) with intestinal failure or congenital diarrheal disorders planned for 2023 SAN FRANCISCO, CA / ACCESSWIRE / May 1, 2023 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") today announced that Napo Therapeutics, the corporation Jaguar established in Italy in 2021 that focuses on expanding access to the Company's oral botanical drug crofelemer for orphan and rare diseases in Europe, is a Platinum Sponsor of the 9th Annual Elite Ped-GI Congress, which takes place May 4-6, 2023 in Abu Dhabi in the United Arab Emirates. The Annual Elite Ped-GI Congress is designed to provide information about high level, clinically significant updates and comprehensive trends relevant to the practice of pediatric gastroenterological, nutrition and liver disorders.

Napo Therapeutics Sponsoring Pediatric Gastroenterology Conference: Elite Ped-GI Congress in Abu Dhabi

91.67% of respondents to a question asking how they see themselves using the product in the future indicated they plan on increasing use of Canalevia®-CA1 over time Canalevia-CA1, Jaguar Health's FDA Conditionally Approved drug for chemotherapy-induced diarrhea (CID) in dogs, is the first and only treatment for CID in dogs to receive any type of approval from the FDA SAN FRANCISCO, CA / ACCESSWIRE / April 27, 2023 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar") today announced the results of a survey of 26 U.S. veterinary oncologists regarding Canalevia-CA1, the company's U.S. Food and Drug Administration (FDA) conditionally approved prescription drug product for the treatment of chemotherapy-induced diarrhea (CID) in dogs. The study was conducted by Jaguar at the Veterinary Cancer Society (VCS) Collaborative Conference, which took place April 19-22, 2023 in Cancun, Mexico.

U.S. Veterinary Oncologists Participating in a New Survey Prefer Canalevia-CA1 Over the Current Standard of Care

Enrollment expected to complete in mid-Q2 2023 As of March 24, 2023, as previously announced, the Company's cash position was approximately $15.3 million SAN FRANCISCO, CA / ACCESSWIRE / April 11, 2023 / Jaguar Health, Inc. (Nasdaq:JAGX) ("Jaguar" or the "Company") today announced that patient enrollment has surpassed 90% in the Company's pivotal Phase 3 OnTarget clinical trial of crofelemer for prophylaxis of diarrhea in adult cancer patients receiving targeted therapy with or without chemotherapy. "Just the week before last - on March 27th - we announced that patient enrollment in OnTarget had reached approximately 80%, and we are very happy to report that enrollment in OnTarget is now already above 90%," said Lisa Conte, Jaguar's president and CEO.

Patient Enrollment Surpasses 90% in Jaguar Health's Pivotal Phase 3 OnTarget Trial of Crofelemer for Cancer Therapy-Related Diarrhea

SAN FRANCISCO, CA / ACCESSWIRE / April 6, 2023 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") today provided an update regarding the Company's efforts to identify trading abnormalities in Jaguar's publicly traded Common Stock that could be markers of potential illegal naked short selling. "As we announced in February, Jaguar engaged Shareholder Intelligence Services, LLC (ShareIntel) to help uncover and address potential trading abnormalities in an effort to ensure that those brokering and trading our stock are compliant with FINRA and SEC rules and regulations governing short selling," said Lisa Conte, Jaguar's president and CEO.

Jaguar Health Provides Update on Monitoring Trading Activity to Identify Possible Illegal Short Selling

Canalevia®-CA1 is the first and only treatment for CID in dogs to receive any type of approval from the FDA In December 2022, FDA increased the maximum number of dogs that can be treated annually with a conditionally approved animal drug from 70,000 to 80,000 SAN FRANCISCO, CA / ACCESSWIRE / March 30, 2023 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") under its Jaguar Animal Health tradename for the veterinary market, today announced that the Company is exhibiting at the Veterinary Cancer Society (VCS) Collaborative Conference, which takes place April 19-22, 2023 in Cancun, Mexico, as part of ongoing promotional activities for Canalevia-CA1 (crofelemer delayed-release tablets). Canalevia-CA1, the company's U.S. Food and Drug Administration (FDA) conditionally approved prescription drug product for the treatment of chemotherapy-induced diarrhea (CID) in dogs, is available from multiple leading veterinary distributors in the U.S. Effective December 14, 2022, the FDA's Center for Veterinary Medicine increased the maximum number of dogs that can be treated annually with a conditionally approved animal drug from 70,000 to 80,000.

Jaguar Animal Health Exhibiting at Veterinary Cancer Society Collaborative Conference for Canalevia-CA1, the Company's FDA Conditionally Approved Drug for Chemotherapy-Induced Diarrhea (CID) in Dogs

Jaguar Health, Inc. (NASDAQ:JAGX ) Q4 2022 Earnings Conference Call March 27, 2023 8:00 AM ET Company Participants Lisa Conte - President & Chief Executive Officer Carol Lizak - Chief Financial Officer Ian Wendt - Chief Commercial Officer Conference Call Participants Operator Good morning. Before I turn the call over to management, I would like to remind you that management may make forward-looking statements relating to such matters as contained growth prospects for the company, uncertainties regarding market acceptance of products and the impact of competitive products and pricing, industry trends and product initiatives, including projects in the development stage which may not achieve scientific objectives or be stringent regulatory requirements.

Jaguar Health, Inc. (JAGX) Q4 2022 Earnings Call Transcript

Prescription product net revenue was approximately $11.9 million for the year ended December 31, 2022 versus approximately $4.3 million for the year ended December 31, 2021, an increase of 178.7%. Prescription product net revenue of approximately $3.3 million in Q4 2022 increased 3.4% over Q3 2022 and increased approximately 57% over prescription product net revenue in Q4 2021.

Jaguar Health Reports 2022 Financial Results - Prescription Revenues up 179% to $11.9 Million

Click here to register for webcast Company plans to file its Annual Report on March 24, 2023 on Form 10-K for the fiscal year ended December 31, 2022 SAN FRANCISCO, CA / ACCESSWIRE / March 24, 2023 / Jaguar Health, Inc. (NASDAQ:JAGX) today announced that the company investor webcast scheduled for Monday, March 27, 2023 to review fourth-quarter 2022 financials and provide corporate updates will now take place at 8:00 a.m. Eastern Daylight Time instead of 8:30 a.m.

Jaguar Health Announces Time Change for March 27th Investor Webcast to 8:00 AM EDT

SAN FRANCISCO, CA / ACCESSWIRE / March 23, 2023 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") and its wholly owned subsidiary Napo Pharmaceuticals (Napo) today announced that Dr. Kelly Shanahan, a former clinician and a metastatic breast cancer patient who is now a full-time independent patient advocate, has joined the Jaguar/Napo Scientific Advisory Board (SAB). "We are very pleased that Dr. Shanahan has joined our SAB," said Pravin Chaturvedi, PhD, Napo and Jaguar's Chair of the Scientific Advisory Board and Chief Scientific Officer.

Leading Cancer Patient Advocate Kelly Shanahan, M.D., Joins Jaguar Health's Scientific Advisory Board

Click here to register for webcast Company plans to file its Annual Report on March 24, 2023 on Form 10-K for the fiscal year ended December 31, 2022 SAN FRANCISCO, CA / ACCESSWIRE / March 21, 2023 / Jaguar Health, Inc. (NASDAQ:JAGX) today announced that the company will conduct an investor webcast on Monday, March 27, 2023 at 8:30 a.m. Eastern Daylight Time to review fourth-quarter 2022 financials and provide corporate updates.

Jaguar Health to Hold Investor Webcast Monday, March 27th at 8:30 AM EDT Regarding Q4 2022 Financials & Corporate Updates

The United Nations General Assembly's theme for the 2023 International Day of Forests is "Forests and Health" as Jaguar collaborates with communities in the Amazonia rainforest to ethically source the active ingredient in its FDA approved botanical drug SAN FRANCISCO, CA / ACCESSWIRE / March 15, 2023 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") today announced that the Company, in advance of International Day of Forests, which takes place March 21, 2023, has achieved an important milestone related to the health of forest ecosystems, people, and communities in the Peruvian Rainforest. For well over a decade, the Company has been collaborating with tropical forest peoples and communities to collect the latex of the Dragon's Blood tree (Croton lechleri), from which crofelemer, the active pharmaceutical ingredient in the Company's FDA-approved oral botanical drug, is extracted and purified.

Jaguar Health Celebrates U.N. International Day of Forests with Milestone of Providing Income to 20,000+ People Living in Tropical Rainforest Communities

AI technology is expected to help make it faster and easier for Mytesi® patients to start and stay on the drug SAN FRANCISCO, CA / ACCESSWIRE / March 13, 2023 / Jaguar Health, Inc. (Nasdaq:JAGX) ("Jaguar" or the "Company") today announced that the Company is developing an artificial intelligence-powered web portal for U.S. healthcare professionals to support patient access to Mytesi (crofelemer), the Company's FDA-approved antidiarrheal prescription drug indicated for the symptomatic relief of noninfectious diarrhea in adult patients with HIV/AIDS on antiretroviral therapy. "We remain committed to reducing access and reimbursement barriers for Mytesi patients.

News for Jaguar Health Stock (JAGX)